Orally inhaled and nasal drug products are complex systems that are highly dependent on interactions between device and formulation components.
Our INTERHALE technologies offer a range of tailored and robust formulation development solutions for all types of pMDIs and DPI device platforms.
Our specialist understanding of the critical material attributes of devices, APIs and excipients enables pre-selection of lead formulations and process requirements to best meet a defined target product profile.
Formulations and processes are subsequently screened to identify critical quality attributes that impact drug product performance. Both formulations and processes are challenged and optimised to ensure that the drug product can be manufactured using the Quality by Design paradigm.
Our extensive expertise has enabled companies to accelerate early phase development programs and expedite first-in-human and proof of concept clinical trials.